1.Establishment of cerebral infarction model in rabbits induced by photochemical injury
Yixiang SHAO ; Shunxing ZHU ; Li DING ; Xiangyang ZHU
Chinese Journal of Tissue Engineering Research 2005;9(29):186-188
BACKGROUND: Cerebral infarctional animal model provide basis for studying human cerebral infarction(CI). There are two traditional CI models, one is reproduced by craniotomy or electro-coagulation by which supplying artery are blocked, another is achieved by embolus or water gelatin micro-thrombosis. But both are difficult to perform and results were instable, which limit the application. Photochemical injury is a novel way to reproduce CI model on experimental animals.OBJECTIVE: To explore a new method of experimental research of local cerebral infarction model which is induced by photochemical injury in rabbits.DESIGN: Single sample studySETTING: Experimental Animal Center of Nantong University.MATERIALS: This study was conducted at the Experimental Animal Center of Nantong University from May to December 2003 (secondary laboratory). Totally 63 Japanese flap-eared rabbits, with birth age of 10-12 month, 33 females and 30 males, with body mass of 1.7-3.3 kg, were randomly selected.METHODS: After anaesthetized, rabbits were cut at the skin for 2 cm long at the crossing of skull center and posterior canthus, skull was exposed and periosteum was separated, then a round skull window with diameter of 0.5 cm was drilled at 0.5 cm left or (right) to sagittal suture and 0.5 cm posterior to coronal suture, after that, 35 g/L rose Bengal was slowly injected from ear-edge vein in dosage of 1 mL/kg by once. About 3minutes later, cold light source (wave length of 540 nm, power of 140 lx)was used to cast light directly onto the skull window for consecutively 8minutes, then incision was sutured. At postoperative 24 hours, neurological defects were scored in five grades [0 score represent no neural impairments; 1 score: the left posterior limbs displayed decreased muscular tension and attenuated contraction reflex; 2 scores: the left posterior limbs were paralyzed, displaying obvious abduction; 3 scores: rabbit displayed obvious adductive drag with body leant to the opposite side; 4 scores: unable to walk and unconsciousness], rabbits were put to death at postoperative 48 hours, infarctional area and volume were determined and pathological changes was also observed.MAIN OUTCOME MEASURES: Limb movement, infarctional area and volume and pathological changes.RESULTS: CI mode was successfully established on 59 rabbits, the sucmean infarctional area was (0.465±0.012) cm2, and the mean volume changes: Infarctional focus displayed typical pathological changes such as impairment, effusion and inflammation. Gentle impairment could be observed in 22 rabbits (37%), medium in 32 rabbits (54%) and severer in 5rabbits (9%).infarction model has multiple advantages, such as easy performance, quick and good repeatability, it can be used to reproduce experimental models for for a long time with low mortality, benefiting for researches on chronic tional size and depth are under control, meeting the need of researches on observed in photochemical injury, which provide basis for study on the efBut there was still some limitations: Since thrombosis was induced at the terminal artery, unfit for the study of lateral circulation and reperfusion;however it was found more similar to human microvascular diseases, thereby incapable of explaining the pathogenesis of other ischemic strokes.
2.EFFECT OF COMPOUND ANTIOXIDANTS ON POSTPRANDIAL GLUCOSE AND INSULIN OF TYPE 2 DIABETES MELLITUS PATIENTS
Cuifeng ZHU ; Fan ZHANG ; Wei LAN ; Xiaoyan XU ; Songchao GUO ; Yixiang SU
Acta Nutrimenta Sinica 1956;0(03):-
Objective: To observe the co-effect of antioxidant compound, soybean isoflavone (SI), VC and VE on glucose and insulin response after oral glucose load in Type 2 Diabetes Mellitus (T2DM) . Methods: 96 selected T2DM patients (50% male, 50% female) were randomly divided into 4 groups according to the dosage of the compound given , none (group B), low dosage (group C), medium dosage (group D) and high dosage (group E) . The normal control (group A) included 24 persons half male, half female . Blood glucose and insulin were determined at OGTT 0 h, 1 h, 2 h, 4 h, 6 h, and the areas under the curve (AUC) of blood insulin/glucose were calculated. Results: The AUC of blood insulin/glucose of male was higher than female in control group, but both were lower than those of four diabetes groups. In both genders of the diabetes groups, blood insulin AUC of group C, D, E was lower than group B, blood glucose AUC of group D, E was lower than group C and B. There was significant difference in blood insulin and glucose AUC of group E as compared to group B in female (P
3.The effects of unilateral urethral obstruction on the expression of AQPs and its implications
Youkong LI ; Xianjue ZHANG ; Guanghua YANG ; Jiajie ZHOU ; Kun DING ; Jianguo WANG ; Min ZHU ; Zhongjun CHEN ; Jinmin ZENG ; Yixiang LIAO
Journal of Chinese Physician 2010;12(10):1332-1336
Objective To investigate the change of AQP1 and AQP2 before and after the release of obstruction and explore the relationship between reabsorption dysfunction of renal tubule and the change of AQPs. Methods The model of unilateral ureter obstruction (UUO) was established by surgery. Western blot and immunohistochemistry were used to study the expression of AQPs before and after obstruction. Results In UUO model, both AQPs began to down-regulate one day after obstruction, the expression of both AQPs became lower one day after the release of obstruction. And they started to up-regulate 7 day after the release of obstruction. AQP2 became normal since 14 days after the release of obstruction, and AQP1 became normal since 21 days after the release of obstruction. Conclusion The expression of AQP1 and AQP2 were descended in hydronephrosis. The dysfunction of renal tubule and the osmotic-dependent polyuria after the release of obstruction in UUO were caused by the down - regulation of AQPs.
4.Clinical analysis of risk factors for lateral cervical lymph node metastasis in stage cN0 papillary thyroid carcinoma and preventive dissection
Yahui MA ; Yixiang LIU ; Guohua YI ; Hongbo ZHU
International Journal of Surgery 2019;46(4):242-246
Objective To discuss the clinical characteristics for lateral cervical lymph node metastasis in stage cN0 papillary thyroid microcarcinoma and significance and feasibility of preventive dissection,and provide reference for clinical treatment.Methods Reviewd the clinical data of 191 patients with stage cN0 papillary thyroid microcarcinoma patients from Jul.2011 to Dec.2016 underwent surgery in the Department of General Surgery of Lianyungang Oriental Hospital.Assessed the need for preventive cervical lymph node dissection.Chisquare test and logistic regression were used to analyze the relationship between cervical lymph node metastasis and gender,age,tumor number,tumor size,capsule infiltration,single and bilateral tumors,Hashimoto's disease,and central lymph node metastasis.Results The positive rate of cervical lymph node metastasis in papillary thyroid microcarcinoma was 27.9% (50/191).Univariate analysis showed that the metastasis of the cervical lymph nodes was associated with infiltration of the capsule,Hashimoto disease,and CLN metastasis (all P < 0.05).Multivariate logistic regression analysis showed that the capsule infiltration (OR =7.563,P =0.000),Hashimoto's disease (OR =4.635,P =0.003),and central lymph node metastasis (OR =3.075,P < 0.001) were able to be independent risk factors for cervical lymph node metastasis.When the positive number of lymph node metastasis in the central region was ≥ 2,the positive rate of cervical lymph nodes was significantly increased (P < 0.001).Eleven patients (5.8%) had temporary recurrent laryngeal nerve palsy,29 patients (15.1%) had transient hypoparathyroidism,and no patients with permanent recurrent laryngeal nerve palsy and hypoparathyroidism.Conclusions The removal of the cervical lymph nodes helps to accurately classify the tumor and assess the risk.It is important to choose the postoperative treatment follow-up plan for patients.For patients with capsule infiltration,Hashimoto's disease,and central lymph node metastasis,cervical lymph node dissection should be routinely performed.
5.Potential Vaccine Targets against Rabbit Coccidiosis by Immunoproteomic Analysis.
Hongyan SONG ; Ronglian DONG ; Baofeng QIU ; Jin JING ; Shunxing ZHU ; Chun LIU ; Yingmei JIANG ; Liucheng WU ; Shengcun WANG ; Jin MIAO ; Yixiang SHAO
The Korean Journal of Parasitology 2017;55(1):15-20
The aim of this study was to identify antigens for a vaccine or drug target to control rabbit coccidiosis. A combination of 2-dimensional electrophoresis, immunoblotting, and mass spectrometric analysis were used to identify novel antigens from the sporozoites of Eimeria stiedae. Protein spots were recognized by the sera of New Zealand rabbits infected artificially with E. stiedae. The proteins were characterized by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF/TOF-MS) analysis in combination with bioinformatics. Approximately 868 protein spots were detected by silver-staining, and a total of 41 immunoreactive protein spots were recognized by anti-E. stiedae sera. Finally, 23 protein spots were successfully identified. The proteins such as heat shock protein 70 and aspartyl protease may have potential as immunodiagnostic or vaccine antigens. The immunoreactive proteins were found to possess a wide range of biological functions. This study is the first to report the proteins recognized by sera of infected rabbits with E. stiedae, which might be helpful in identifying potential targets for vaccine development to control rabbit coccidiosis.
Coccidiosis*
;
Computational Biology
;
Eimeria
;
Electrophoresis
;
HSP70 Heat-Shock Proteins
;
Immunoblotting
;
Mass Spectrometry
;
Rabbits
;
Sporozoites
6.Clinical features of patients with EGFR mutation-positive non-small cell lung cancer and brain metastases
Chinese Journal of Radiation Oncology 2022;31(5):468-472
Advanced non-small cell lung cancer (NSCLC) patients are commonly with brain metastases, leading to poor survival and quality of life. Epidermal growth factor receptor (EGFR) is common sensitive mutation type in NSCLC. Compared with other molecular types, it has different molecular biological characteristics. For patients with brain metastases and EGFR-mutated advanced NSCLC, EGFR-tyrosine kinase inhibitors can prolong overall survival and improve intracranial and extracranial control rate. To understand the characteristics of brain metastases of patients with sensitively EGFR-mutated NSCLC, the incidence, onset time, site, number and size of lesions, symptoms, targeted treatment effect and disease outcomes were reviewed, which can provide reference for interventional timing and local treatment technology selection of local treatment for brain parenchymal metastases.
7.Clinical Features of EGFR Mutation Negative in Patients with Non-small Cell Lung Cancer and Brain Metastases.
Chinese Journal of Lung Cancer 2021;24(1):43-48
In addition to rare incidence of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 receptor kinase (ROS1) positive patients, patients with brain metastases of non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) sensitive mutation have no effective systemic therapy at present, and the overall prognosis is poor. Since the low blood-brain barrier permeability of chemotherapy drugs, the local treatment plays an important role in brain metastases. To understand the clinical characteristics and treatment of brain parenchymal metastases in patients with NSCLC and EGFR mutation negative, we reviewed the incidence, onset time, site, numbers, size, symptom, therapeutic effect and disease evolution in them, which can provide reference for interventional timing and local treatment technology selection of local treatment for brain parenchymal metastases.
.
8.Current Progress and Future Developments of Antibody Drug Conjugates in Lung Cancer.
Chinese Journal of Lung Cancer 2022;25(7):468-476
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.
.
Antibodies, Monoclonal/therapeutic use*
;
Antineoplastic Agents/therapeutic use*
;
Antineoplastic Agents, Immunological/therapeutic use*
;
Humans
;
Immunoconjugates/therapeutic use*
;
Lung Neoplasms/drug therapy*
;
Neoplasms/drug therapy*
9.Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer.
Ziyi XU ; Puyuan XING ; Di MA ; Yixiang ZHU ; Jianming YING ; Junling LI
Chinese Journal of Lung Cancer 2019;22(2):111-117
Standard treatment for resectable IIIa/N2 non-small-cell lung cancer (NSCLC) is still under debate. Optional treatments include chemotherapy, radiotherapy and surgery, other options include target therapy and immunotherapy. Multidisciplinary treatment has therefore been emphasized by various clinical trials, including bimodality strategy which has been defined as chemotherapy plus surgery or chemotherapy plus radiotherapy, and trimodality treatment which refers to chemotherapy plus surgery and radiotherapy. However, there is still no consensus on the optimal strategy on treating resectable IIIa/N2 NSCLC. Therefore, we reviewed a series of phase II and III clinical trials as well as some meta-analyses and case reports to compare the efficacy of different strategies on survival of cN2 NSCLC, and concluded that for resectable IIIa/N2 NSCLC surgery is recommended, and that strategy of chemotherapy plus surgery may not achieve better survival than that of chemotherapy plus radiotherapy. Size of tumor as well as lymph nodes should be taken into account when choosing optimal therapy, so that promising individualized strategy could be given to patients with resectable stage IIIa/N2 NSCLC.
.
Clinical Trials as Topic
;
Combined Modality Therapy
;
Humans
;
Lung Neoplasms
;
drug therapy
;
radiotherapy
;
surgery
;
therapy
;
Meta-Analysis as Topic
;
Neoplasm Staging
;
Treatment Outcome
10.Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.
Yixiang ZHU ; Chengcheng LIU ; Ziyi XU ; Zihua ZOU ; Tongji XIE ; Puyuan XING ; Le WANG ; Junling LI
Chinese Medical Journal 2023;136(21):2551-2561
BACKGROUND:
The brain is a common metastatic site in patients with non-small cell lung cancer (NSCLC), resulting in a relatively poor prognosis. Systemic therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is recommended as the first-line treatment for EGFR -mutated, advanced NSCLC patients. However, intracranial activity varies in different drugs. Thus, brain metastasis (BM) should be considered when choosing the treatment regimens. We conducted this network meta-analysis to explore the optimal first-line therapeutic schedule for advanced EGFR -mutated NSCLC patients with different BM statuses.
METHODS:
Randomized controlled trials focusing on EGFR-TKIs (alone or in combination) in advanced and EGFR -mutant NSCLC patients, who have not received systematic treatment, were systematically searched up to December 2021. We extracted and analyzed progression-free survival (PFS) and overall survival (OS). A network meta-analysis was performed with the Bayesian statistical model to determine the survival outcomes of all included therapy regimens using the R software. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to compare intervention measures, and overall rankings of therapies were estimated under the Bayesian framework.
RESULTS:
This analysis included 17 RCTs with 5077 patients and 12 therapies, including osimertinib + bevacizumab, aumolertinib, osimertinib, afatinib, dacomitinib, standards of care (SoC, including gefitinib, erlotinib, or icotinib), SoC + apatinib, SoC + bevacizumab, SoC + ramucirumab, SoC + pemetrexed based chemotherapy (PbCT), PbCT, and pemetrexed free chemotherapy (PfCT). For patients with BM, SoC + PbCT improved PFS compared with SoC (HR = 0.40, 95% CI: 0.17-0.95), and osimertinib + bevacizumab was most likely to rank first in PFS, with a cumulative probability of 34.5%, followed by aumolertinib, with a cumulative probability of 28.3%. For patients without BM, osimertinib + bevacizumab, osimertinib, aumolertinib, SoC + PbCT, dacomitinib, SoC + ramucirumab, SoC + bevacizumab, and afatinib showed superior efficacy compared with SoC (HR = 0.43, 95% CI: 0.20-0.90; HR = 0.46, 95% CI: 0.31-0.68; HR = 0.51, 95% CI: 0.34-0.77; HR = 0.50, 95% CI: 0.38-0.66; HR = 0.62, 95% CI: 0.43-0.89; HR = 0.64, 95% CI: 0.44-0.94; HR = 0.61, 95% CI: 0.48-0.76; HR = 0.71, 95% CI: 0.50-1.00), PbCT (HR = 0.29, 95% CI: 0.11-0.74; HR = 0.31, 95% CI: 0.15-0.62; HR = 0.34, 95% CI: 0.17-0.69; HR = 0.34, 95% CI: 0.18-0.64; HR = 0.42, 95% CI: 0.21-0.82; HR = 0.43, 95% CI: 0.22-0.87; HR = 0.41, 95% CI: 0.22-0.74; HR = 0.48, 95% CI: 0.31-0.75), and PfCT (HR = 0.14, 95% CI: 0.06-0.32; HR = 0.15, 95% CI: 0.09-0.26; HR = 0.17, 95% CI: 0.09-0.29; HR = 0.16, 95% CI: 0.10-0.26; HR = 0.20, 95% CI: 0.12-0.35; HR = 0.21, 95% CI: 0.12-0.39; HR = 0.20, 95% CI: 0.12-0.31; HR = 0.23, 95% CI: 0.16-0.34) in terms of PFS. And, SoC + apatinib showed relatively superior PFS when compared with PbCT (HR = 0.44, 95% CI: 0.22-0.92) and PfCT (HR = 0.21, 95% CI: 0.12-0.39), but similar PFS to SoC (HR = 0.65, 95% CI: 0.42-1.03). No statistical differences were observed for PFS in patients without BM between PbCT and SoC (HR = 1.49, 95% CI: 0.84-2.64), but both showed favorable PFS when compared with PfCT (PfCT vs. SoC, HR = 3.09, 95% CI: 2.06-4.55; PbCT vs. PfCT, HR = 0.14, 95% CI: 0.06-0.32). For patients without BM, osimertinib + bevacizumab was most likely to rank the first, with cumulative probabilities of 47.1%. For OS, SoC + PbCT was most likely to rank first in patients with and without BM, with cumulative probabilities of 46.8%, and 37.3%, respectively.
CONCLUSION
Osimertinib + bevacizumab is most likely to rank first in PFS in advanced EGFR -mutated NSCLC patients with or without BM, and SoC + PbCT is most likely to rank first in OS.
Humans
;
Carcinoma, Non-Small-Cell Lung/metabolism*
;
Afatinib/therapeutic use*
;
Lung Neoplasms/metabolism*
;
Bevacizumab/therapeutic use*
;
Bayes Theorem
;
Network Meta-Analysis
;
Protein Kinase Inhibitors/therapeutic use*
;
Pemetrexed/therapeutic use*
;
ErbB Receptors/genetics*
;
Brain Neoplasms/genetics*
;
Mutation/genetics*